Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Insulin receptor substrate 2 (IRS2) deficiency delays liver fibrosis associated with cholestatic injury.

Villar-Lorenzo A, Rada P, Rey E, Marañón P, Arroba AI, Santamaría B, Sáiz J, Rupérez FJ, Barbas C, García-Monzón C, Valverde ÁM, González-Rodríguez Á.

Dis Model Mech. 2019 Jul 16;12(7). pii: dmm038810. doi: 10.1242/dmm.038810.

2.

Development and Validation of Hepamet Fibrosis Scoring System A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.

Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Ming-Hua Z, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry.

Clin Gastroenterol Hepatol. 2019 Jun 11. pii: S1542-3565(19)30602-0. doi: 10.1016/j.cgh.2019.05.051. [Epub ahead of print]

PMID:
31195161
3.

Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.

Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Trevaskis JL, Grimsby J, Rondinone CM, Valverde ÁM.

Sci Rep. 2018 Nov 7;8(1):16461. doi: 10.1038/s41598-018-33949-z.

4.

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.

Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, Huo X, Aller R, García-Monzón C, Teresa Arias-Loste M, Bugianesi E, Miele L, Gallego-Durán R, Fischer J, Berg T, Liddle C, Qiao L, George J, Eslam M.

J Hepatol. 2019 Mar;70(3):494-500. doi: 10.1016/j.jhep.2018.10.021. Epub 2018 Oct 31.

PMID:
30389552
5.

The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.

Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1260-1270. doi: 10.1111/apt.15015. Epub 2018 Oct 23.

PMID:
30353552
6.

Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.

Cruces-Sande M, Vila-Bedmar R, Arcones AC, González-Rodríguez Á, Rada P, Gutiérrez-de-Juan V, Vargas-Castrillón J, Iruzubieta P, Sánchez-González C, Formentini L, Crespo J, García-Monzón C, Martínez-Chantar ML, Valverde ÁM, Mayor F Jr, Murga C.

Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3655-3667. doi: 10.1016/j.bbadis.2018.09.027. Epub 2018 Sep 24.

PMID:
30261289
7.

Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis.

García-Monzón C, Petrov PD, Rey E, Marañón P, Del Pozo-Maroto E, Guzmán C, Rodríguez de Cía J, Casado-Collado AJ, Vargas-Castrillón J, Saez A, Miquilena-Colina ME, Lo Iacono O, Castell JV, González-Rodríguez Á, Jover R.

Am J Pathol. 2018 Dec;188(12):2800-2810. doi: 10.1016/j.ajpath.2018.07.028. Epub 2018 Sep 22.

PMID:
30248338
8.

Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349].

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, López Miranda J, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego-Durán R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476. doi: 10.1016/j.gastrohep.2018.05.011. English, Spanish. No abstract available.

PMID:
29929828
9.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 7. English, Spanish. Erratum in: Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476.

PMID:
29631866
10.

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis.

González-Rodríguez Á, Valdecantos MP, Rada P, Addante A, Barahona I, Rey E, Pardo V, Ruiz L, Laiglesia LM, Moreno-Aliaga MJ, García-Monzón C, Sánchez A, Valverde ÁM.

Mol Metab. 2018 Jan;7:132-146. doi: 10.1016/j.molmet.2017.10.008. Epub 2017 Oct 31.

11.

PGE2 induces apoptosis of hepatic stellate cells and attenuates liver fibrosis in mice by downregulating miR-23a-5p and miR-28a-5p.

Brea R, Motiño O, Francés D, García-Monzón C, Vargas J, Fernández-Velasco M, Boscá L, Casado M, Martín-Sanz P, Agra N.

Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):325-337. doi: 10.1016/j.bbadis.2017.11.001. Epub 2017 Nov 3.

12.

Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver.

Nuñez-Garcia M, Gomez-Santos B, Buqué X, García-Rodriguez JL, Romero MR, Marin JJG, Arteta B, García-Monzón C, Castaño L, Syn WK, Fresnedo O, Aspichueta P.

J Lipid Res. 2017 Sep;58(9):1903-1915. doi: 10.1194/jlr.M078980. Epub 2017 Jul 28.

13.

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.

Valdecantos MP, Pardo V, Ruiz L, Castro-Sánchez L, Lanzón B, Fernández-Millán E, García-Monzón C, Arroba AI, González-Rodríguez Á, Escrivá F, Álvarez C, Rupérez FJ, Barbas C, Konkar A, Naylor J, Hornigold D, Santos AD, Bednarek M, Grimsby J, Rondinone CM, Valverde ÁM.

Hepatology. 2017 Mar;65(3):950-968. doi: 10.1002/hep.28962. Epub 2017 Jan 30.

PMID:
27880981
14.

Research update for articles published in EJCI in 2014.

Agra RM, Al-Daghri NM, Badimon L, Bodi V, Carbone F, Chen M, Cubedo J, Dullaart RP, Eiras S, García-Monzón C, Gary T, Gnoni A, González-Rodríguez Á, Gremmel T, Hafner F, Hakala T, Huang B, Ickmans K, Irace C, Kholová I, Kimer N, Kytö V, März W, Miazgowski T, Møller S, Montecucco F, Niccoli G, Nijs J, Ozben S, Ozben T, Papassotiriou I, Papastamataki M, Reina-Couto M, Rios-Navarro C, Ritsch A, Sabico S, Seetho IW, Severino A, Sipilä J, Sousa T, Taszarek A, Taurino F, Tietge UJ, Tripolino C, Verloop W, Voskuil M, Wilding JP.

Eur J Clin Invest. 2016 Oct;46(10):880-94. doi: 10.1111/eci.12671. No abstract available.

PMID:
27571922
15.

Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.

Motiño O, Agra N, Brea Contreras R, Domínguez-Moreno M, García-Monzón C, Vargas-Castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-Sanz P.

Biochim Biophys Acta. 2016 Sep;1862(9):1710-23. doi: 10.1016/j.bbadis.2016.06.009. Epub 2016 Jun 15.

16.

Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.

Bozic M, Guzmán C, Benet M, Sánchez-Campos S, García-Monzón C, Gari E, Gatius S, Valdivielso JM, Jover R.

J Hepatol. 2016 Oct;65(4):748-757. doi: 10.1016/j.jhep.2016.05.031. Epub 2016 May 28.

PMID:
27245430
17.

Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.

Ampuero J, Ranchal I, Gallego-Durán R, Pareja MJ, Del Campo JA, Pastor-Ramírez H, Rico MC, Picón R, Pastor L, García-Monzón C, Andrade R, Romero-Gómez M.

J Gastroenterol Hepatol. 2016 Sep;31(9):1611-8. doi: 10.1111/jgh.13335.

PMID:
26946071
18.

Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.

Zubiete-Franco I, García-Rodríguez JL, Martínez-Uña M, Martínez-Lopez N, Woodhoo A, Juan VG, Beraza N, Lage-Medina S, Andrade F, Fernandez ML, Aldámiz-Echevarría L, Fernández-Ramos D, Falcon-Perez JM, Lopitz-Otsoa F, Fernandez-Tussy P, Barbier-Torres L, Luka Z, Wagner C, García-Monzón C, Lu SC, Aspichueta P, Mato JM, Martínez-Chantar ML, Varela-Rey M.

J Hepatol. 2016 Feb;64(2):409-418. doi: 10.1016/j.jhep.2015.08.037. Epub 2015 Sep 21.

19.

Regulation of MicroRNA 183 by Cyclooxygenase 2 in Liver Is DEAD-Box Helicase p68 (DDX5) Dependent: Role in Insulin Signaling.

Motiño O, Francés DE, Mayoral R, Castro-Sánchez L, Fernández-Velasco M, Boscá L, García-Monzón C, Brea R, Casado M, Agra N, Martín-Sanz P.

Mol Cell Biol. 2015 Jul;35(14):2554-67. doi: 10.1128/MCB.00198-15. Epub 2015 May 11.

20.

Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.

García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME.

Liver Int. 2015 Aug;35(8):1983-91. doi: 10.1111/liv.12813. Epub 2015 Mar 5.

PMID:
25708133
21.

S-Adenosylmethionine increases circulating very-low density lipoprotein clearance in non-alcoholic fatty liver disease.

Martínez-Uña M, Varela-Rey M, Mestre D, Fernández-Ares L, Fresnedo O, Fernandez-Ramos D, Gutiérrez-de Juan V, Martin-Guerrero I, García-Orad A, Luka Z, Wagner C, Lu SC, García-Monzón C, Finnell RH, Aurrekoetxea I, Buqué X, Martínez-Chantar ML, Mato JM, Aspichueta P.

J Hepatol. 2015 Mar;62(3):673-81. doi: 10.1016/j.jhep.2014.10.019. Epub 2014 Oct 18.

22.

Increased hepatic CD36 expression with age is associated with enhanced susceptibility to nonalcoholic fatty liver disease.

Sheedfar F, Sung MM, Aparicio-Vergara M, Kloosterhuis NJ, Miquilena-Colina ME, Vargas-Castrillón J, Febbraio M, Jacobs RL, de Bruin A, Vinciguerra M, García-Monzón C, Hofker MH, Dyck JR, Koonen DP.

Aging (Albany NY). 2014 Apr;6(4):281-95.

23.

Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD.

González-Rodríguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM, Piacentini M, Muntané J, Boscá L, García-Monzón C, Martín-Sanz P, Valverde ÁM.

Cell Death Dis. 2014 Apr 17;5:e1179. doi: 10.1038/cddis.2014.162.

24.

Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease.

García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez de Cía J, Sáez A, Porrero JL, Vargas-Castrillón J, Chávez-Jiménez E, Soto-Fernández S, Díaz A, Gallego-Durán R, Madejón A, Miquilena-Colina ME.

Eur J Clin Invest. 2014 Jan;44(1):65-73. doi: 10.1111/eci.12192. Epub 2013 Nov 23.

PMID:
24134687
25.

Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.

Vazquez-Chantada M, Gonzalez-Lahera A, Martinez-Arranz I, Garcia-Monzon C, Regueiro MM, Garcia-Rodriguez JL, Schlangen KA, Mendibil I, Rodriguez-Ezpeleta N, Lozano JJ, Banasik K, Justesen JM, Joergensen T, Witte DR, Lauritzen T, Hansen T, Pedersen O, Veyrie N, Clement K, Tordjman J, Tran A, Le Marchand-Brustel Y, Buque X, Aspichueta P, Echevarria-Uraga JJ, Martin-Duce A, Caballeria J, Gual P, Castro A, Mato JM, Martinez-Chantar ML, Aransay AM.

Hepatology. 2013 Feb;57(2):505-14. doi: 10.1002/hep.26052. Epub 2012 Nov 27.

PMID:
22961556
26.

High insulin levels are required for FAT/CD36 plasma membrane translocation and enhanced fatty acid uptake in obese Zucker rat hepatocytes.

Buqué X, Cano A, Miquilena-Colina ME, García-Monzón C, Ochoa B, Aspichueta P.

Am J Physiol Endocrinol Metab. 2012 Aug 15;303(4):E504-14. doi: 10.1152/ajpendo.00653.2011. Epub 2012 Jun 12.

27.

Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression.

Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM.

J Proteome Res. 2012 Apr 6;11(4):2521-32. doi: 10.1021/pr201223p. Epub 2012 Mar 15.

28.

Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver.

Moya M, Benet M, Guzmán C, Tolosa L, García-Monzón C, Pareja E, Castell JV, Jover R.

PLoS One. 2012;7(1):e30014. doi: 10.1371/journal.pone.0030014. Epub 2012 Jan 6.

29.

Autophagy protects cells from HCV-induced defects in lipid metabolism.

Vescovo T, Romagnoli A, Perdomo AB, Corazzari M, Ciccosanti F, Alonzi T, Nardacci R, Ippolito G, Tripodi M, Garcia-Monzon C, Lo Iacono O, Piacentini M, Fimia GM.

Gastroenterology. 2012 Mar;142(3):644-653.e3. doi: 10.1053/j.gastro.2011.11.033. Epub 2011 Dec 7.

PMID:
22155365
30.

Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C.

Gut. 2011 Oct;60(10):1394-402. doi: 10.1136/gut.2010.222844. Epub 2011 Jan 26.

PMID:
21270117
31.

Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S.

Clin Sci (Lond). 2011 Mar;120(6):239-50. doi: 10.1042/CS20100387.

PMID:
20929443
32.

Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C.

García-Monzón C, Lo Iacono O, Mayoral R, González-Rodríguez A, Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Vargas-Castrillón J, Casado M, Boscá L, Valverde AM, Martín-Sanz P.

J Hepatol. 2011 Jan;54(1):142-52. doi: 10.1016/j.jhep.2010.06.021. Epub 2010 Aug 27.

33.

[Obesity and liver disease].

Miquilena Colina ME, García Monzón C.

Gastroenterol Hepatol. 2010 Oct;33(8):591-604. doi: 10.1016/j.gastrohep.2009.12.009. Epub 2010 Mar 4. Review. Spanish.

PMID:
20206411
34.

A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats.

Buqué X, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, Aspichueta P, Ochoa B.

J Lipid Res. 2010 Mar;51(3):500-13. doi: 10.1194/jlr.M001966. Epub 2009 Sep 24.

35.

Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial.

Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Sáez A, Rizza P, Capone I, Rapicetta M, Chionne P, Capobianchi M, Selleri M, Castilletti C, Belardelli F, Iacono OL, García-Monzón C.

Vaccine. 2009 Sep 18;27(41):5654-60. doi: 10.1016/j.vaccine.2009.07.014. Epub 2009 Jul 25.

PMID:
19635606
36.

Liver growth factor antifibrotic activity in vivo is associated with a decrease in activation of hepatic stellate cells.

Díaz-Gil JJ, García-Monzón C, Rúa C, Martín-Sanz P, Cereceda RM, Miquilena-Colina ME, Machín C, Fernández-Martínez A, García-Cañero R.

Histol Histopathol. 2009 Apr;24(4):473-9. doi: 10.14670/HH-24.473.

PMID:
19224450
37.

The pathogen receptor liver and lymph node sinusoidal endotelial cell C-type lectin is expressed in human Kupffer cells and regulated by PU.1.

Domínguez-Soto A, Aragoneses-Fenoll L, Gómez-Aguado F, Corcuera MT, Clária J, García-Monzón C, Bustos M, Corbí AL.

Hepatology. 2009 Jan;49(1):287-96. doi: 10.1002/hep.22678.

PMID:
19111020
38.

[Endoglin: structure, biological functions, and role in fibrogenesis].

García-Pozo L, Miquilena-Colina ME, Lozano-Rodríguez T, García-Monzón C.

Rev Esp Enferm Dig. 2008 Jun;100(6):355-60. Review. Spanish. No abstract available.

39.

The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats.

Díaz-Gil JJ, García-Monzón C, Rúa C, Martín-Sanz P, Cereceda RM, Miquilena-Colina ME, Machín C, Fernández-Martínez A, García-Cañero R.

Histol Histopathol. 2008 May;23(5):583-91. doi: 10.14670/HH-23.583.

PMID:
18283643
40.

Colitis by Cryptosporidium as initial manifestation of acquired immunodeficiency syndrome.

Pita-Fernández L, Vargas-Castrillón J, Pazos C, Gallego I, García-Monzón C.

Rev Esp Enferm Dig. 2006 Aug;98(8):621-3. English, Spanish. No abstract available.

41.

Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.

Clemente M, Núñez O, Lorente R, Rincón D, Matilla A, Salcedo M, Catalina MV, Ripoll C, Iacono OL, Bañares R, Clemente G, García-Monzón C.

J Viral Hepat. 2006 Sep;13(9):625-32.

PMID:
16907850
42.

Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.

Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C.

Gut. 2006 Mar;55(3):374-9. Epub 2005 Sep 8.

43.

Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells.

García-Mediavilla MV, Sánchez-Campos S, González-Pérez P, Gómez-Gonzalo M, Majano PL, López-Cabrera M, Clemente G, García-Monzón C, González-Gallego J.

J Hepatol. 2005 Oct;43(4):606-13.

PMID:
16112247
44.

Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins.

Apolinario A, Majano PL, Lorente R, Núñez O, Clemente G, García-Monzón C.

J Viral Hepat. 2005 Jan;12(1):27-37.

PMID:
15655045
45.

[Autoimmune hepatitis in patients with a diagnosis of multiple sclerosis].

Núñez O, de Andrés C, Alvarez E, García-Monzón C, Clemente G.

Gastroenterol Hepatol. 2004 Nov;27(9):521-4. Spanish.

PMID:
15544737
46.

Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.

Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, López-Cabrera M, Boscá L, Clemente G, García-Monzón C, Martín-Sanz P.

Gut. 2004 Nov;53(11):1665-72.

47.

Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women.

Saez A, Losa M, Lo Iacono O, Lozano C, Alvarez E, Pita L, Garcia-Monzón C.

Hepatogastroenterology. 2004 Jul-Aug;51(58):1104-8.

PMID:
15239255
48.

Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.

Apolinario A, Diago M, Lo Iacono O, Lorente R, Pérez C, Majano PL, Clemente G, García-Monzón C.

Aliment Pharmacol Ther. 2004 Mar 1;19(5):551-62.

PMID:
14987324
49.

Role of chemokines in the pathogenesis of liver diseases.

Apolinario Fernández de Sousa A, García Monzón C.

Rev Esp Enferm Dig. 2003 Sep;95(9):614-20, 607-13. Review. English, Spanish.

PMID:
14738406
50.

[Role of cyclooxygenase-2 in the pathogenesis of chronic liver diseases].

Núñez Martínez O, Clemente Ricote G, García Monzón C.

Med Clin (Barc). 2003 Nov 29;121(19):743-8. Review. Spanish.

PMID:
14678698

Supplemental Content

Loading ...
Support Center